Viromed Medical AG Completes EUR 2 Million Capital Increase to Fund Working Capital

Viromed Medical AG has successfully completed a capital increase, issuing 450,000 new registered no-par value shares at a placement price of EUR 4.50 per share, according to a release distributed via NEWMEDIAWIRE. The gross proceeds of approximately EUR 2 million will be used to finance the company's working capital. The move signals the company's effort to secure liquidity as it pursues growth in the medical technology sector.

The capital increase was executed by partially utilizing the Authorized Capital 2025 and with the exclusion of shareholders' subscription rights, meaning existing shareholders were not offered the opportunity to purchase new shares on a pro-rata basis. Subject to the registration of the implementation of the capital increase in the commercial register, the share capital will rise from EUR 21,250,000 by EUR 450,000 to EUR 21,700,000. The increase represents a roughly 2.1% expansion of share capital, a relatively modest dilution that nevertheless provides the company with fresh funds.

The decision to exclude subscription rights can be significant for investors, as it allows the company to place shares quickly with selected investors, potentially streamlining the capital-raising process. However, it also means existing shareholders' ownership stakes are diluted without the chance to participate. The placement price of EUR 4.50 per share provides a reference point for the company's valuation at the time of the transaction.

Viromed Medical AG specializes in the development, manufacture, and distribution of medical products. Since October 2022, the company has been listed on the stock exchange, and its operating business centers on the distribution of innovative cold plasma technology for medical applications through its wholly owned subsidiary, Viromed Medical GmbH. The company serves a broad customer base in the DACH region (Germany, Austria, and Switzerland) and beyond. Further details about the company can be found at www.viromed-medical-ag.de.

The capital infusion is intended to support working capital needs, which could include inventory, operational expenses, or expansion initiatives. For a company focused on advancing cold plasma technology in medicine, adequate working capital is essential to fund research, development, and commercialization efforts. Cold plasma technology has gained attention for its potential in wound healing, sterilization, and other medical applications, and Viromed aims to further advance its use in the coming years.

The successful completion of the capital increase underscores investor confidence in Viromed's business model and growth prospects. By raising EUR 2 million, the company bolsters its financial flexibility and can continue to invest in its operations without immediate pressure to seek alternative financing. The transaction also demonstrates the company's ability to access capital markets, which could be important for future funding rounds.

For stakeholders, the key takeaway is that Viromed has secured additional resources to execute its strategy. The exclusion of subscription rights may raise governance questions, but the company appears to have prioritized speed and certainty in securing funds. As Viromed continues to develop and distribute cold plasma technology, the additional capital provides a foundation for pursuing growth opportunities in the medical technology landscape. The original release is available on www.newmediawire.com.